A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older

Christy A. Comeaux, Marco Testa, Efi Gymnopoulou, Arangassery Rosemary Bastian, Mauricio L. Nogueira, Hongxing Pan, Fengcai Zhu, Viktoriia Fursenko, William B. Smith, Patricia Junquera, Joris Menten, Matteo Loi, Edem Bassey Effiom, Archana M. Jastorff, Karin Weber, Ann R. Falsey, Benoit Callendret, Esther Heijnen

Open source

DOI: 10.1016/j.ebiom.2026.106513
Published: 2026-11
Container: eBioMedicine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2026.106513,
  title = {A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older},
  author = {Christy A. Comeaux and Marco Testa and Efi Gymnopoulou and Arangassery Rosemary Bastian and Mauricio L. Nogueira and Hongxing Pan and Fengcai Zhu and Viktoriia Fursenko and William B. Smith and Patricia Junquera and Joris Menten and Matteo Loi and Edem Bassey Effiom and Archana M. Jastorff and Karin Weber and Ann R. Falsey and Benoit Callendret and Esther Heijnen},
  year = {2026},
  journal = {eBioMedicine},
  doi = {10.1016/j.ebiom.2026.106513},
  url = {https://doi.org/10.1016/j.ebiom.2026.106513}
}

RIS

TY  - JOUR
TI  - A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older
AU  - Christy A. Comeaux
AU  - Marco Testa
AU  - Efi Gymnopoulou
AU  - Arangassery Rosemary Bastian
AU  - Mauricio L. Nogueira
AU  - Hongxing Pan
AU  - Fengcai Zhu
AU  - Viktoriia Fursenko
AU  - William B. Smith
AU  - Patricia Junquera
AU  - Joris Menten
AU  - Matteo Loi
AU  - Edem Bassey Effiom
AU  - Archana M. Jastorff
AU  - Karin Weber
AU  - Ann R. Falsey
AU  - Benoit Callendret
AU  - Esther Heijnen
PY  - 2026
JO  - eBioMedicine
DO  - 10.1016/j.ebiom.2026.106513
UR  - https://doi.org/10.1016/j.ebiom.2026.106513
ER  -

APA

Comeaux, C. A., Testa, M., Gymnopoulou, E., Bastian, A. R., Nogueira, M. L., Pan, H., Zhu, F., Fursenko, V., Smith, W. B., Junquera, P., Menten, J., Loi, M., Effiom, E. B., Jastorff, A. M., Weber, K., Falsey, A. R., Callendret, B., & Heijnen, E. (2026). A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older. eBioMedicine. https://doi.org/10.1016/j.ebiom.2026.106513

Source records

crossref · retrieved 2026-11-08T19:42:46.875Z